| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205
Submitted 20 March 2003 ; accepted in final form 17 April 2003
 |
ABSTRACT |
|---|
 TOP ABSTRACT GlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
angiogenesis; receptor-ligand interactions; kinetics; synergy; mathematical or computational model
45 kDa (2, 17). They have distinct binding characteristics to the two primary VEGF-family receptors on endothelial cells: VEGF receptor (VEGFR)-1 binds both PlGF and VEGF, whereas VEGFR2 binds only VEGF. VEGF is a known inducer of vascular permeability and angiogenesis in vivo and cultured endothelial cells respond to VEGF with increased survival, proliferation, and migration; there are several comprehensive reviews on the subject (38, 56). Adult PlGF-null mice demonstrate reduced pathological angiogenesis and vascular leakage (9, 35). PlGF is angiogenic in certain situations (59), is chemotactic for endothelial cells and monocytes in vitro (11), and can increase vascular permeability and survival in vivo (1, 41), but in many cases it acts by augmenting the VEGF-induced effect (43). PlGF increases the response of cultured endothelial cells to VEGF-induced survival, proliferation, and migration (9). In in vitro assays of hydraulic conductivity and proliferation, PlGF increased the response to VEGF in a cell-type-specific and time-dependent manner (13). PlGF synergy is specific to VEGF; it does not augment basic fibroblast growth factor responses.
Two pathways by which the addition of PlGF could impact on VEGF-induced effects have been suggested. First, PlGF, which binds VEGFR1 but not VEGFR2, may displace VEGF from VEGFR1 to VEGFR2: a concept known as ligand shifting (43). Second, the PlGF may play a more direct role signaling into the endothelial cell via VEGFR1. Evidence that this signaling takes place has been presented at least once (9); however, the issue of VEGFR1 signaling in endothelial cells remains controversial. Both of these pathways may occur at the same time, complicating the process of dissecting the functions of the various receptors. This study is concerned with quantifying the ligand shift effect, the displacement of VEGF by PlGF, with the use of a mathematical model. A particular set of recent experiments in which synergy was observed (9) is recreated in silico.
In these three in vitro angiogenesis-associated assays (for survival, proliferation, and migration) the cells examined were microvascular endothelial cells obtained from both wild-type and PlGF-null mice. The PlGF-null cells did not respond as strongly to VEGF as did those from wild-type mice, but the addition of exogenous PlGF along with VEGF restored the response in a dose-dependent fashion, suggesting that the wild-type endothelial cells produced sufficient PlGF to augment the VEGF response. For the PlGF-null cells, the VEGF-induced increase in migration rate was 3-fold; the addition of PlGF made it 16-fold. Proliferation rate increase by VEGF was 50% without and 280% with PlGF. Survival was only slightly improved by VEGF, with the apoptosis rate falling 7%; the addition of PlGF caused the rate to fall by 75%. In each of these cases, PlGF administered alone did not have a significant effect on the process but acted only in concert with VEGF. This study recreates in silico these assays performed on the PlGF-null cells. We compare the following two cases: 1) exogenous VEGF is added (PlGF–case) and 2) exogenous VEGF and PlGF are added together (PlGF+ case) to determine the relative importance of ligand shifting.
The three assays being modeled share a similar geometry. A layer of endothelial cells is in contact with a fluid layer containing serum and growth factors in a well of a 24-well plate. The well is assumed to be symmetrical and we ignore the edge effects so that we examine only the variation in the vertical direction, that is, from the cell surface to the free surface of the fluid layer. At the start of the assay, 100 ng/ml of VEGF alone (PlGF–case) or 100 ng/ml each of VEGF and PlGF (PlGF+ case) were added to the media above the cultured cells. For the duration of the assay, the growth factors diffused toward the endothelial cells and bound to the cell surface receptors, from which they may be rereleased into the medium or internalized; we model all of these transport processes. The assay measurement was a cell count at the completion of the assay. In the model, we noted instead the predicted concentration of ligand-receptor complexes formed on the endothelial cell surface. It is with the interpretation of these calculated values, and of their relationship to the outcome of the experimental assays that we are primarily concerned in this paper. It should be noted that this is the first computational model describing transport and binding of VEGF to its receptors. We have constructed this model to describe unsteady in vitro situations as a first step to modeling more complex, dynamic in vivo situations.
|
Glossary |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
|
MODEL OF MULTILIGAND MULTIRECEPTOR INTERACTIONS |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
The growth factors used in the assays are the human VEGFA165 splice isoform (hVEGFA165) and the mouse heparin-binding PlGF isoform (mPlGF2); the concentrations of these ligands are denoted as V and P (M), respectively. The endothelial cells are microvascular in origin, obtained from PlGF-null mice by a subcutaneous matrigel pellet that becomes vascularized (9). We assume that only mouse VEGFR1 and VEGFR2 receptors interact with the ligands at the cell surface; the concentrations of the receptors are denoted as R1 and R2 (mol/cm2), respectively. Three surface ligand-receptor complexes are also included in the model: VR1, VR2, and PR1. Other VEGF and PlGF receptors on endothelial cells, such as the neuropilins, are not considered in this study; their role is considered secondary to that of VEGFR1 and VEGFR2. The effect of heparan sulfate proteoglycans (HSPGs), which modulate VEGF-family binding, is assumed to be included in the effective rate constants.
Two classes of species are represented in the model: volumetric (growth factors) and surface (receptors and ligand-receptor complexes). We assume symmetry in the well, that is, the concentrations of ligands and receptors are spatially uniform parallel to the plane of the cell surface; the equations are thus reduced to one spatial dimension (z) perpendicular to the cell surface. The evolution over time of the volumetric species concentrations (e.g., 
V/t) is represented by Eqs. 1 and 2, where DV and DP are the diffusivities of VEGF and PlGF (cm2/s), respectively. The assay is 24 h in duration; thus ligand degradation in the medium is neglected. No factors in the fluid that could bind the ligands, for example, soluble VEGFR1 or secreted extracellular matrix (ECM) proteins, are included at this point; their effect is investigated in calculations presented in the APPENDIX
 | (1) |
 | (2) |
 | (3) |
 | (4) |
 | (5) |
 | (6) |
 | (7) |
 | (8) |
 | (9) |
 | (10) |
 | (11) |
Model Parameters
The existing experimental literature was researched for specific or representative values for the model parameters. The representative set of parameters used in this model is shown in Table 1, along with the ranges used for the sensitivity analysis. This is the first such compilation of these values.
|
The initial ligand concentration used in the assays is 100 ng/ml. For a 45-kDa ligand, this is equivalent to 2.22 nM. VEGF is initially present at this concentration; PlGF is initially present at this concentration only in the PlGF+ case. The number of receptors on the endothelial cell surface is heavily dependent on the cell type, tissue of origin, vessel of origin, and the activation state of the cell. Microvascular endothelial cells from the human colon demonstrated 79,900 VEGFR1 and 231,300 VEGFR2 receptors per cell (54). Endothelial cells from larger vessels may have fewer receptors; typical VEGFR1 and VEGFR2 populations for human umbilical vein endothelial cells (HUVECs) are 500–3,000 and 5,850–12,000 receptors/cell, respectively (6, 31, 39). Stimulated cells can also have increased receptor populations (7). For this experiment, the microvascular cells are assumed to have receptor populations of 80,000 and 230,000 for VEGFR1 and VEGFR2, respectively. Endothelial cell size is an important determinant of receptor concentration; for our purposes, size means the area of plasma membrane in contact with the fluid, to which ligands can bind. Endothelial cells from hamster arterioles have effective (side-facing flow) surface areas of 1,000–1,550 µm2 (21); the values for dog aortic cells were in the range of 400–700 µm2 (30). Assuming a cell area of 1,000 µm2, we estimate the initial receptor concentrations as 13.3 and 38.3 fmol/cm2 for VEGFR1 and VEGFR2, respectively; because of the uncertainty of both the receptor populations and the cell size, a range of receptor concentrations about these values was examined.
The Kd values of hVEGFA165 to VEGFR1 and VEGFR2 on HUVECs have been determined in the ranges of 9–26 and 100–770 pM, respectively (6, 31, 39, 53). The measured values for the cell surface receptors on microvascular endothelial cells from human colon were 130 and 675 pM, respectively (54). The binding affinity of human PlGF for VEGFR1 on HUVECs was shown to be 230 pM (43), and the binding affinity of the mouse homologs of these molecules is assumed to be the same. The binding affinity of hVEGFA165 for mouse VEGFR2 (mVEGFR2) in a cell-free system was shown to be 340 pM (25), and that is the value assumed here; the ratio of affinities for mVEGFR1 and mVEGFR2 is estimated to be in a similar ratio to the ratio for the human receptors, and thus the value of Kd for hVEGFA165-mVEGFR1 binding is taken to be 25 pM.
Because binding affinity is the ratio of the off and on rates, we use the affinity estimates as constraints on the values of these kinetic rates. Cell-free experiments using human ligand and immobilized human receptors measured values for the individual kinetic rates, kon and koff. Justification for the suitability of using rates measured in such an experiment can be taken from the observation of equivalence of rates of binding to monomeric and predimerized VEGFR2 (12). For hVEGFA165, the measured on rates were 4 x 106 M–1·s–1 binding to human VEGFR1, 3.6 x 106 M–1·s–1 binding to human VEGFR2, and 1.2 x 106 M–1·s–1 binding to mVEGFR2 (12, 25, 51). The off rates from the same experiments were 30 x 10–6, 134 x 10–6, and 410 x 10–6 s–1, respectively. With the use of these rates and the constraint of the binding affinities, the rates for hVEGFA165 and mouse mPlGF2 binding to mouse VEGF receptors were estimated. The values of koff were assumed to be 95 x 10–6, 410 x 10–6, and 345 x 10–6 s–1 and the values of kon were taken as 3.8 x 106, 1.2 x 106, and 1.5 x 106 M–1·s–1 for hVEGFA165-mVEGFR1, hVEGFA165-mVEGFR2, and mPlGF2-mVEGFR1, respectively. Again, a range of values was examined. Although kinetic rates are obtained in cell-free systems and do not incorporate the effects of HSPGs on the cell surface, we examined the reported time course of binding of VEGF to HUVECs (6), and the kinetic rates obtained differed from those used here by a factor of four. As shown in the sensitivity analysis, this is insufficient to affect the conclusions of the model (see RESULTS).
The rate of internalization of ligand-receptor complexes was estimated from experiments in which the quantities of VEGF bound to microvascular cell surface and of internalized VEGF were measured over time after addition of VEGF to fluid over the cells (54). We have applied a simplified version of the model presented here for a single growth factor and single receptor population to these data to obtain a value of 2.8 x 10–4 s–1 for the internalization rate of VEGF-receptor complexes. This value compares favorably with those obtained by estimation of instantaneous internalization rate (4.3 x 10–4 s–1) of VEGF in HUVECs (6) and the measured internalization rates of basic fibroblast growth factor-receptor complexes (2–7 x 10–4 s–1) (16, 47). A value for the internalization rate of unoccupied VEGF receptors was not available from the experimental literature; in some receptor systems, the rate of internalization of unoccupied receptors is lower than that of ligand-receptor complexes, e.g., by up to a factor of 10 for epidermal growth factor receptors (28). We assume a value of 10–5 s–1 for the internalization rate of unoccupied VEGF receptors, and in the sensitivity analysis (see RESULTS) we note that, whereas the model is sensitive to increases in this parameter, this is due to the corresponding increase in the dependent insertion rates of receptors (see below).
Insertion rates of newly synthesized receptors were estimated from the receptor population and the internalization rates of the unoccupied receptors; in the absence of ligand, the internalization and receptor insertion rates at the cell membrane are balanced, to give a steady receptor population. Thus values for the insertion rates of 0.8 and 2.3 receptors·cell–1·s–1 for VEGFR1 and VEGFR2, or 1.3 x 10–19 and 3.8 x 10–19 mol·cm–2·s–1, respectively, were calculated; these rates are similar to those of the EGFR system (48). We assume that this rate is constant during the experiment. The variation due to insertion rate was not examined because it is a dependent variable.
The diffusivity of the ligands in aqueous solution is estimated to be 10–6 cm2/s based on molecular weight (5). A range of values from 10–5 to 10–7 cm2/s was examined to estimate sensitivity to this parameter.
These PlGF-null cells do not secrete PlGF; however, they may secrete VEGF. We model zero VEGF secretion and discuss the effects of autocrine VEGF secretion by the endothelial cells later. The final parameter of importance is the height of media above the cells, h. This is estimated to be 1 mm, which represents 0.2 ml of media in one well of a 24-well plate. The sensitivity of the results to this parameter was also examined using a range of 10–1–10 mm.
Solution
Equations 1–10 are a complete set of coupled, nonlinear partial and ordinary differential equations. The equations were nondimensionalized, and, using a fully implicit finite-difference scheme on a one-dimensional grid, we obtained a series of coupled nonlinear time-dependent algebraic equations that were solved iteratively at each time step. Iterations were complete when subsequent refinements resulted in a <10–10 fractional change. An adaptive time step size was used to decrease the total computation time required while still achieving convergence at early time points.
|
RESULTS |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
The molecular species of interest here are the ligand-receptor complexes as the gateways to cell signaling. In particular, the validity of the ligand shifting hypothesis rests on an increase in the number of VEGF-VEGFR2 complexes formed in the presence of PlGF and VEGF together. The model was applied to the case of addition of VEGF alone (PlGF–case) and then to that of addition of both VEGF and PlGF (PlGF+ case). The synergistic effects of the added PlGF were then investigated by examining the differences between these two cases.
The number of ligand-receptor complexes predicted by the model to be present on the cell surface during the assay is shown in Fig. 1A. The number of VEGFR1 complexes is a sum of VEGF-VEGFR1 and PlGF-VEGFR1 complexes. Growth factors bind rapidly to the unoccupied receptors early in the time course, and are then internalized. The number of complexes reaches a peak at 10 min (VEGFR1) and 25 min (VEGFR2) and then settles to a significantly lower complex concentration due to elevated internalization of occupied receptors relative to that of unoccupied receptors. At this scale, a difference in the number of occupied VEGFR1 receptors between the PlGF– and PlGF+ cases can be seen at early time points, and a smaller change in the number of occupied VEGFR2 receptors is discernable. The absolute change between the PlGF– and PlGF+ cases is shown in Fig. 1B. Three components are observed to the change in complex formation in the PlGF+ case: an early transient increase (of <30 min), followed by a decrease in complexes caused by increased internalization of receptors, and finally a small elevation at later times. Transient increases of up to 14,000 VEGFR1 complexes per cell are predicted, with a maximal increase in VEGFR2 complexes of 6,000 per cell. The elevated complex formation at later times is due to decreased internalization of VEGF in the PlGF+ case, where less VEGF removed from the system keeps the receptor occupancy higher. The absolute increases of Fig. 1B are translated into percentage increases, plotted in Fig. 1C. The model predicts the maximal increase in VEGFR2 complexes to be 5% and the total increase in VEGFR2 complex formation over the duration of the assay to be <1%.
|
In contrast, the predicted transient increase in the number of VEGFR1 complexes is more significant, as much as 43%; the formation of both PlGF-VEGFR1 and VEGF-VEGFR1 complexes is shown in Fig. 2A. This shows that the increase has two components: a decrease in VEGF-VEGFR1 formation and an increase in PlGF-VEGFR1 formation. The predicted percentage of VEGFR1 complexes that are PlGF containing are shown in Fig. 2B.
|
The in vitro assays being modeled demonstrated an increase in the efficacy of VEGF of 5- to 10-fold due to the addition of PlGF. The simulation results suggest that the observation of synergy in the in vitro assays was unlikely to be due to the displacement of VEGF by PlGF from VEGFR1 to VEGFR2 and signaling through VEGFR2 alone, the displacement giving only a transient 5% increase in VEGFR2 complex formation. They further predict a more significant increase in VEGFR1 complex formation and a change in the proportion of ligands bound to that receptor, suggesting a role for VEGFR1 signaling in the observed synergy and a change in the nature of VEGFR1 signaling on addition of PlGF. This supports the experimental findings of Carmeliet et al. (9), which demonstrated an abrogation of the PlGF synergy effects on addition of anti-VEGFR1 antibodies. Blocking that receptor should increase the VEGFR2 complex formation further by freeing more VEGF.
Effect of Growth Factor Concentration
The reason for the small change in VEGFR2 complex formation is that the ligand concentrations in this experiment are very high, higher than physiological concentrations and higher than the binding affinities of the receptors, which leads to high fractional occupancies of both receptors; the predicted fractional occupancies are shown in Fig. 3. Whereas VEGF may be displaced from VEGFR1, there is little unoccupied VEGFR2 for it to bind to. Thus we would expect ligand shifting by PlGF to be predicted at lower ligand concentrations, and, by simulating the conditions with different initial ligand concentrations, this is precisely what we see (Fig. 4A). Figure 4A shows the maximal percent change in VEGF-VEGFR2 complex formation for a range of initial ligand concentrations. The original conditions, corresponding to the in vitro assays modeled in Fig. 1, are marked in Fig. 4 by a solid circle. The effect of high ligand concentration on fractional occupancy is particularly important in explaining the small amount of shifting outside the early transient, when the receptors have had time to become occupied. The transient, on the other hand, is a measure of the rate at which the receptors become occupied by the ligands, which is directly dependent on the concentration of ligand available for binding; this is effectively double for VEGFR1 in the PlGF+ case, due to the presence of both ligands. In contrast, VEGFR2 does not bind PlGF, and there is a much smaller increase in the effective ligand concentration it sees. This small increase is due to the decrease in VEGF bound by VEGFR1 as it binds PlGF, but this increase is small relative to the excess of ligand already in place. The maximal fractional occupancies of the receptors for this range of initial conditions is shown in Fig. 4, B and C, demonstrating that significant ligand shifting occurs for high VEGFR1 occupancy and low VEGFR2 occupancy. This supports the interpretation that high VEGFR1 occupancy allows PlGF to displace large quantities of VEGF, raising the effective VEGF concentration in the medium, which in turn can increase binding to the abundant unoccupied VEGFR2 that are available under these conditions. In fact, the reason there is an observable change in the VEGFR2 complex formation is that the step change in ligand concentration, with only unoccupied receptors on the surface, causes a rapid depletion of the ligand close to the cell surface. This decreased local ligand concentration causes the sensitivity to PlGF. Were the diffusivity faster, the local ligand concentration would be maintained from the large pool of ligand above the cells instead of requiring time to equilibrate.
|
|
Figure 4 shows that high PlGF concentrations can cause large ligand shifts in low VEGF concentration situations. However, these high percentage changes can be misleading. Figure 5 shows that the predicted number of VEGF-VEGFR2 complexes formed is only a weak function of PlGF concentration and a strong function of VEGF concentration. These results suggest that experimental observations that high concentrations of PlGF can augment low VEGF concentrations and elicit a response similar to a higher VEGF concentration (55) are not directly due to ligand shifting, as the displacement achieved by PlGF does not appear to cause sufficient VEGF-VEGFR2 formation to compensate for the decreased VEGF concentration. VEGFR1 complexes, in contrast, are increased in the low VEGF-high PlGF situation (data not shown). We would have to conclude at this point that the experimental finding of synergy in that experiment would also be due to VEGFR1 signaling rather than displacement of VEGF to VEGFR2.
|
Note that we have modeled the endothelial cells throughout as secreting no VEGF. Secretion would increase the concentration of VEGF in the fluid and thus further decrease the ligand shifting effects.
Effects of Soluble Receptors and ECM
It is important to consider the possibility that other factors are present in the assays that we excluded from the model, but which may have an impact on our interpretation of the results. It is possible, for example, that these endothelial cells are secreting factors that can sequester the growth factors. These factors include soluble VEGFR1 (sVEGFR1) and ECM components, to which both VEGFA165 and PlGF2 bind. To model the effect of these factors, the equations were extended to include these components, as volumetric species that could bind both PlGF and VEGF. The additional and modified equations required are detailed in the APPENDIX; additional parameters for binding were obtained and are listed in Table 2. The results of the simulations show that a thin layer of ECM proteins secreted and remaining close to the cell surface did not significantly increase the ligand shifting in this experiment, up to micromolar concentrations of ECM binding sites. Serum levels of sVEGFR1 in the healthy adult were reported to be 28 ng/ml, or 250 pM (32). This concentration of soluble receptor in the medium would cause a maximum change in VEGF-VEGFR2 formation of 8% (see Fig. 6). The change in VEGFR1 complex formation remains >40%. As the soluble receptor approaches the same concentration as the ligands, it is sequestering significant quantities of both, reducing the effective free ligand concentration available for surface binding, and thus reducing the fractional occupancies of the cell surface receptors and increasing the efficacy of the added PlGF in shifting VEGF. However, it is unlikely that the cells are secreting sVEGFR1 at the rates required to build up this level of concentration. Assuming that no sVEGFR1 was present at the beginning of the time period, secretion of sVEGFR1 would have to exceed 40 molecules·cell–1·s–1 to achieve this increase in VEGF-VEGFR2 complex formation.
|
|
Sensitivity Analysis
The uncertainty in some model parameters was noted earlier, due to both biological variability and uncertainty in measurement, and it is thus necessary to check the sensitivity of the model results to those parameters. In particular, the number of receptors on the endothelial cell surface was not known directly for the cell type used in the assays but was inferred from a similar cell type. The effect on PlGF-induced VEGF-VEGFR2 formation of variation in VEGFR1 populations is shown in Fig. 7A; this uses the predicted maximal change in VEGF-VEGFR2 complex formation as a marker of ligand shifting (other parameters are as for the original model). The displacement effect predicted at high VEGFR1 concentration reflects the fact that to observe shifting, the amount of VEGF displaced from the receptor must be large relative to the amount of VEGF already present in the medium. As the concentration of VEGFR1 becomes very large, it sequesters larger quantities of ligand at the same fractional occupancy. The results are similarly dependent on VEGFR2 concentration, an increase in that population increasing the initial depletion of ligand close to the surface. VEGFR1 and VEGFR2 concentrations higher than those used in the model have not been observed.
|
A decrease in cell size would lead to an increase in effective receptor concentration; however, the change required to see an effect is large. If the assumption of confluence implicit in the analysis were to be discarded, the loss of total cellular area would result in fewer receptors and, hence, lower total internalization of growth factor. This results in maintenance of higher ligand concentrations and thus decreases ligand shift.
The sensitivity of the results of Fig. 1 to variation in complex internalization rate is shown in Fig. 7B. Over a large range (10–6–10–3 s–1), this internalization rate does not impact on the observed response of VEGF-VEGFR2 formation to PlGF. The same does not hold true for the internalization rate of unoccupied receptors, as increases in this rate must increase the constitutive insertion rate of receptors (see Model Parameters). A high turnover of receptors causes a greater depletion of ligand from the medium, and hence lowers fractional occupancies, which can lead to ligand shifting. For an unoccupied receptor internalization rate equal to the occupied receptor rate (which implies a receptor insertion rate increase of 28-fold), the increase in VEGFR2 ligation is 22%, and the increase in VEGFR1 ligation is still significantly (sevenfold) greater than the VEGFR2 increase.
The sensitivity of the results to variation in the other parameters used was also examined. The height of the fluid layer is directly related to the volume of medium-growth factor mixture added to the well. The effect of changing this height is to change the total quantity of ligand available for binding. The initial concentration is the same, but a lower total quantity can lead to depletion in the concentration as the ligand molecules are internalized during the course of the experiment. Thus lowering the height, equivalent to using a smaller volume of medium, has a similar effect to increasing concentration of cell surface receptors.
The sensitivity to ligand concentration is dependent on the value of diffusivity and the values of the kinetic rates of binding; a lower value for diffusivity (or a higher value for kinetic rates) would increase the concentration gradients in the fluid, and thus the receptors would experience a lower effective ligand concentration, enlarging the effective ligand-shifting space shown in Fig. 4A. An order of magnitude decrease in diffusivity (to 10–7 cm2/s) results in a maximal increase in VEGF-VEGFR2 complex formation of 21% and an increase in VEGFR1 complex formation of 72%. A range of variation in the binding affinities or the individual kinetic rates (see Table 1) did not increase the PlGF sensitivity significantly.
|
DISCUSSION |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
The amount of ligand shifting is a direct consequence of the high growth factor concentrations administered in the assays; that ligand shifting is observed at all is due to transient ligand depletion close to the cell surface. Similar conclusions can be arrived at by examining three other experimental models of PlGF-VEGF synergy. In a recent gene expression study (55), the concentration of VEGF required to induce maximal gene expression in HUVECs was found to be 1 nM, but the same gene expression response was obtained by using 0.5 nM VEGF and 10 nM of a VEGFR1-selective VEGF mutant. These ligand concentrations are marked on Fig. 5 as solid squares; the concentrations of growth factors involved suggest little additional VEGFR2 complex formation. We would have to conclude that the experimental finding of synergy in that experiment would also be due to VEGFR1 signaling rather than displacement of VEGF to VEGFR2. High concentrations of PlGF (>100 pM) were shown to augment VEGF-induced proliferation at a submaximal VEGF concentration (<1 pM)in adrenal cortex capillary endothelial cells (43). However, the proliferation response was augmented much more than would be predicted in Fig. 4A and approached proliferation rates achieved at high VEGF concentrations (220 pM), which would be predicted by Fig. 5 to have considerably higher VEGFR2 complex formation. The time-dependent synergy observed in bovine aortic endothelial cells is also unlikely to be due to ligand shifting, again due to the high growth factor concentrations used (13).
The issue of PlGF synergy is intimately associated with the function of VEGFR1 on endothelial cells. In embryonic development, VEGFR1 appears to work as a dummy receptor, a VEGF sink, decreasing the amount of VEGF that is available to bind to VEGFR2: this coincides with a prevalence of the soluble form of VEGFR1 (9). Consistent with this, VEGFR1-null mice die at embryonic day 8.5 due to overproduction of endothelial cells (18), and mice in which VEGFR1 is expressed without its intracellular tyrosine kinase domain exhibit a defect in monocyte migration but not in embryonic vascular synthesis (23).
Signaling by the receptor in adult cells is a controversial issue; monocytes express VEGFR1 but not VEGFR2 and the receptor appears to transduce activation and migration signals (11). A signaling role in hematopoietic progenitor cells has also been demonstrated (10). In adult endothelial cells, a demonstration of active VEGFR1 signaling has proved elusive, because the tyrosine kinase activity of VEGFR1 is less than that of VEGFR2, but there is some indirect evidence. Were VEGFR1 acting as a dummy receptor to sequester VEGF, then antisense VEGFR1 should increase the signaling through VEGFR2. However, antisense VEGFR1 abrogated new capillary formation induced by VEGF in mouse as effectively as did antisense VEGFR2 (37). Tumors grew more slowly in mice that were null for the VEGFR1 tyrosine kinase domain than wild-type mice (22). Antibodies to VEGFR1 suppressed angiogenesis and tumor growth in mice (36, 49). However, in all of these cases, the explanation may be abrogation of VEGFR1 signaling in the monocytes (and hence inflammation), rather than in the endothelial cells. A diabody which blocks growth factor interactions with both receptors was shown to be more effective at inhibiting VEGF-induced migration and proliferation in cultured endothelial cells than antibodies to VEGFR2 alone (34), and an antibody for VEGFR1 blocked the synergistic effects of PlGF in the experimental assays modeled in this paper (9). VEGFR1 has been shown to transduce signals for actin reorganization (contributing to cell migration) in HUVECs (27), and VEGFR1 also downregulated VEGFR2 proliferation, via phosphatidylinositol 3-kinase (57) and VEGF-induced nitric oxide release, thus promoting stable capillary formation by HUVECs (8).
The present model describes an effect observed in cultured ECs in vitro, and while synergistic effects are also noted in vivo, it should be noted that extending the model directly to an in vivo situation is not straightforward. The concentrations of ligands added in the experimental assay (2.22 nM) may not be representative of physiological concentrations, but obtaining interstitial concentrations of ligands and the receptor populations of cells in situ is difficult. Measured tissue concentrations of VEGF range from 0.9 to 884 ng/g tissue (58); assuming an interstitial volume of 20%, this gives interstitial concentrations of 0.2–100 nM. However, this represents both free VEGF and VEGF sequestered in the ECM. Depending on the isoforms of VEGF prevalent in the tissue (40), the VEGF available for receptor binding may be a small percentage of the total (24). PlGF tissue concentrations in normal placentas were <4 ng/g tissue (0.5 nM interstitial PlGF); however, choriocarcinoma tissue concentration was 116 ng/g tissue (42). Measured plasma concentrations of VEGF range from 0.5 to 2 pM and PlGF has been measured at 11 pM (14, 20, 26, 32, 33), and serum concentrations have been measured in the ranges of 0.5–4 and 1–11 pM, respectively (44, 52). At these lower concentrations, we cannot rule out ligand shifting as a part of the synergistic response (see Fig. 4A). In addition, the presence of soluble receptors and ECM proteins would lower diffusivity and change the transport characteristics of the growth factors, leading to increased possibility of ligand shifting (see Fig. 6). However, the number of receptors on the endothelial cell surface can vary over several orders of magnitude, even for the same cell type, due to cytokines, hypoxia, or other activating factors; the explanted cells for which receptor populations are measured likely overestimate the number in vivo due to overstimulation of the cells, decreasing likelihood of ligand shifting (see Fig. 7A). Experimental measurements of the receptor populations in vivo would be of great benefit in this analysis. The transients predicted for the in vitro model are due to a step change in ligand concentration; in vivo, there is a baseline secretion rate of growth factors, and changes in effective ligand concentration are gradual, due to an increase in secretion and subsequent diffusion to the endothelial cell surface. Thus the results of a similar analysis for the in vivo situation remain to be obtained.
The analysis in this study is based on a continuum model due to the high growth factor concentrations, and although this method has been used applied in previous studies of other ligand families (15, 19, 46), a stochastic model could be used to verify the range of applicability of the continuum assumption when working with small concentrations of ligands and receptors, which appears to be the case in vivo. The analysis also relies on an assumed relationship between the formation of the ligand-receptor complexes and the generation of signals into the cell; we do not treat this signaling explicitly, using instead the formation of the complexes as a surrogate marker for the quantity of signaling. This relationship may not in fact be linear and may be "tuned" to small changes in the number of signaling complexes; information on the signaling from the receptors can be included to more accurately estimate the relative contributions of the receptors. One example of such signaling is an increase in the production of either or both of the VEGF receptors, due to signaling of VEGF-VEGFR2 complexes. Such an increase has the possibility of creating a significant feedback effect, which augments the increase in complex formation. This increase in the insertion rate of receptors can deplete the ligand growth factor in the medium further, decreasing the fractional occupancy and increasing the ligand shift. Because of the time required to synthesize and transport the new receptors to the surface, the early transient complex formation would be unchanged; however, an impact could be seen later in the time course.
This is the first model of VEGF transport and interactions with its receptors. To make the interpretation of the results tractable, we applied the model to an experiment with simple conceptual design and geometry. We have been able to reach conclusions that are of importance for understanding the mechanisms of interaction between VEGF and PlGF and their two receptors on the cell surface, VEGFR1 and VEGFR2. The model has limitations that could be relaxed in future studies. First, we considered only one isoform of VEGF, namely VEGFA165. There are at least six VEGFA splice isoforms in the human that compete for the same receptors and that have different binding affinities to the proteoglycans of the extracellular matrix. VEGF-PlGF heterodimers were also not included because their presence requires a cell type producing both VEGF and PlGF, but should be included in future models to be applied to the in vivo conditions. Second, there are additional cell surface VEGF receptors whose potential importance has recently been demonstrated: neuropilin-1 and -2 and VEGFR3. Third, explicit treatments of receptor dimerization and more complex, multireceptor interactions (including, for example, HSPGs) are additional features that may be important. The model presented here can easily be extended to include multiple VEGF isoforms, additional receptors, and complex interactions; care is required in selecting the values of parameters of the system and interpretation of the results, because of the growing complexity of the system. Fourth, feedback mechanisms, including the upregulation or suppression of ligand and receptor production should be included, as these would have significant effects on the receptor populations on the cell surface. Finally, increased knowledge of the intracellular trafficking of internalized VEGF, PlGF, and their receptors would make it possible to include processes such as ligand degradation and exocytosis and receptor recycling.
On the basis of the mathematical model presented here, we predict that VEGF signaling through VEGFR2 alone is unlikely to produce the observed response to VEGF and PlGF in cultured endothelial cells and that VEGFR1 is also involved in the signaling.
|
APPENDIX |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
Extension of the model to include representative ECM binding sites and sVEGFR1, the concentrations of which are represented as M and S1 (M), respectively, was accomplished by formulating Eqs. A1–A11 in addition to Eqs. 3–11. Equations A1 and A2 replace Eqs. 1 and 2 and include the binding to the volumetric species
 | (A1) |
 | (A2) |
 | (A3) |
 | (A4) |
 | (A5) |
 | (A6) |
 | (A7) |
 | (A8) |
 | (A9) |
 | (A10) |
 | (A11) |
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
|
REFERENCES |
|---|
|
TOPABSTRACTGlossaryMODEL OF MULTILIGAND...RESULTSDISCUSSIONAPPENDIXREFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  E. Kurtagic, M. P. Jedrychowski, and M. A. Nugent Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity Am J Physiol Lung Cell Mol Physiol, March 1, 2009; 296(3): L534 - L546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Ji, F. Mac Gabhann, and A. S. Popel Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3740 - H3749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Alarcon and K. M Page Mathematical models of the VEGF receptor and its role in cancer therapy J R Soc Interface, April 22, 2007; 4(13): 283 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mac Gabhann, J. W. Ji, and A. S. Popel VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle J Appl Physiol, February 1, 2007; 102(2): 722 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Gabhann and A. S. Popel Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H459 - H474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Mac Gabhann and A. S. Popel Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2851 - H2860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Filion and A. S. Popel Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H263 - H279. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
).
.
